Rituxan

February 11, 2019

Rituxan Plus Chemo Fails to Benefit Newly Diagnosed Primary CNS Lymphoma Patients in Clinical Trial

News

Adding Rituxan (rituximab) to standard first-line chemotherapy did not improve disease outcomes for people with primary central nervous system (CNS) lymphoma in a Phase 3 clinical trial, results show. The ... Read more

February 6, 2019

BI-1206 Earns Orphan Drug Designation as Mantle Cell Lymphoma Treatment

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BioInvent’s antibody BI-1206 for the treatment of mantle cell lymphoma. “This orphan designation for BI-1206 is very good news ... Read more

December 14, 2018

Truxima Shows Safety, Efficacy Comparable to Rituxan in Advanced Follicular Lymphoma

News

Truxima (rituximab-abbs), a biosimilar to Rituxan (rituxumab), has similar safety and efficacy as the original product in patients with advanced follicular lymphoma after two years, results from a Phase 3 ... Read more

December 5, 2018

5F9-Rituxan Combo Eliminates Tumors in One-third of DLBCL, Follicular Lymphoma Patients

News

A combination of Forty Seven‘s macrophage checkpoint inhibitor Hu5F9-G4 and Rituxan (rituximab) is safe and completely eliminated tumors in one-third of non-Hodgkin’s lymphoma patients included in a Phase 1b trial. The trial, ... Read more

November 13, 2018

Rituxan Shows Similar Benefit With or Without Chemo in Indolent Lymphomas, Study Finds

News

Using Rituxan (rituximab) as first-line treatment for indolent — or slow-growing — lymphomas leads to similar long-term survival as regimens containing both Rituxan and chemotherapy, a study shows. The approach also eliminated ... Read more

September 19, 2018September 19, 2018

Rituxan-Revlimid Combo Effective in Treating Advanced Follicular Lymphoma, Study Shows

News

Patients with previously untreated follicular lymphoma may soon be able to replace a regimen of chemotherapy and Rituxan (rituximab) with Rituxan and Revlimid (lenalidomide) after a Phase 3 trial showed similar effectiveness for ... Read more

August 28, 2018August 28, 2018

FDA Approves Imbruvica-Rituxan Combo Therapy for Rare Type of Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) plus Rituxan (rituximab) for the treatment of patients with a rare type of non-Hodgkin’s lymphoma called Waldenström’s macroglobulinemia (WM). This represents the first and only chemotherapy-free combination ... Read more

July 30, 2018July 31, 2018

Revlimid-Rituxan Combo May Replace Chemo, Delay Decline for Some Lymphoma Patients, Phase 3 Trial Shows

News

Adding Revlimid (lenalidomide) to Rituxan (rituximab) in the treatment of follicular lymphoma and marginal zone lymphoma patients who failed at least one prior therapy significantly delays disease progression or death, a Phase 3 ... Read more

June 19, 2018

Trial of Betalutin-Rituxan Combo as Second-line Follicular Lymphoma Therapy Poised to Launch in Norway

News

A Phase 1b trial evaluating a combination of Betalutin (177Lu-satetraxetan-lilotomab) and Rituxan (rituximab) as a second-line therapy for follicular lymphoma will begin soon in Norway following Nordic Nanovector receiving all necessary approvals. The trial, called Archer-1, ... Read more

June 18, 2018

FDA Approves Venclexta-Rituxan Combo Therapy for CLL/SLL Patients

News

The U.S. Food and Drug Administration (FDA) has approved a combination treatment of Venclexta (venetoclax tablets) with Rituxan (rituximab) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma ... Read more